Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients.

OBJECTIVE To evaluate patient and physician factors associated with prevention of glucocorticoid-induced osteoporosis and to describe temporal trends in screening and prevention of glucocorticoid-induced osteoporosis. METHODS Using databases from a national managed care organization, enrollees who had been prescribed glucocorticoids (taken for at least 60 days) during an 18-month period were identified. Administrative data from January 2001 through June 2003 and linked survey data from October 2003 were examined for measurement of bone mass, prescription of antiresorptive medication, and use of over-the-counter calcium and/or vitamin D treatment. Factors associated with screening and bone-protective therapies were identified using multivariable logistic regression, focusing on physician specialty and survey respondent ethnicity. Trends in glucocorticoid-induced osteoporosis prevention were assessed using administrative data from 2001-2003 versus 1995-1998. RESULTS We identified 6,281 patients who were prescribed glucocorticoids in 2001-2003 (mean +/- SD prescribed prednisone-equivalent dosage 16 +/- 14 mg/day). Forty-two percent underwent bone mass measurement and/or were prescribed bone-protective medication; rates were lowest for men (25%). Compared with patients of internists, the odds of bone mass measurement were lowest among patients prescribed glucocorticoids by family physicians (odds ratio [OR] 0.56 [95% confidence interval] [95% CI] 0.30-1.04) and highest among patients prescribed glucocorticoids by rheumatologists (OR 1.48 [95% CI 1.06-2.08]). Patients prescribed glucocorticoids by gastroenterologists were less likely to be treated with antiresorptive agents (OR 0.49 [95% CI 0.28-0.86]). African American patients were less likely than white patients to be screened (OR 0.55 [95% CI 0.40-0.75]) or treated (OR 0.71 [95% CI 0.51-0.98]). The frequency of bone mass measurement among glucocorticoid-treated patients in 2001-2003 increased 3-fold compared with 1995-1998, and the use of prescription antiresorptive medication increased approximately 2-fold. CONCLUSION Despite significant temporal increases in the frequency of screening for and treatment of glucocorticoid-induced osteoporosis, absolute rates remain low, especially among men, African Americans, and patients of certain physician specialties.

[1]  N. Powe,et al.  Association between Screening for Osteoporosis and the Incidence of Hip Fracture , 2005, Annals of Internal Medicine.

[2]  Olof Johnell,et al.  A Meta‐Analysis of Prior Corticosteroid Use and Fracture Risk , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  Stanley B. Cohen,et al.  Oral glucocorticoid use is associated with an increased risk of fracture , 2004, Osteoporosis International.

[4]  C. Cooper,et al.  Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. , 2003, Arthritis and rheumatism.

[5]  S. Gabriel,et al.  Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. , 2003, Arthritis and rheumatism.

[6]  I. Chantler,et al.  Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service , 2003, Annals of the rheumatic diseases.

[7]  J. Jacobs,et al.  Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? , 2003, Clinical and experimental rheumatology.

[8]  J. Katz,et al.  Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. , 2002, Arthritis and rheumatism.

[9]  C. Cooper,et al.  The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis , 2002, Osteoporosis International.

[10]  Susan Mehle,et al.  Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. , 2002, Mayo Clinic proceedings.

[11]  M. Cesari,et al.  Treatment of osteoporosis among older adults discharged from hospital in Italy , 2001, European Journal of Clinical Pharmacology.

[12]  D L Conn,et al.  Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[13]  N. Holford,et al.  Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy , 2001, European Journal of Clinical Pharmacology.

[14]  J. Allison,et al.  Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. , 2001, The Journal of rheumatology.

[15]  C. Cooper,et al.  Public health impact of adverse bone effects of oral corticosteroids. , 2001, British journal of clinical pharmacology.

[16]  J. Gurwitz,et al.  Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. , 2001, Archives of internal medicine.

[17]  Walton Sumner,et al.  Preferences for Fractures and Other Glucocorticoid-Associated Adverse Effects among Rheumatoid Arthritis Patients , 2001 .

[18]  M. Ahern,et al.  Prevention of corticosteroid induced osteoporosis in inpatients recently discharged from a tertiary teaching hospital. , 2001, The Journal of rheumatology.

[19]  C. Cooper,et al.  Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. , 2000, Rheumatology.

[20]  L. Moreland,et al.  Practice Pattern Variation Among Internal Medicine Specialists in the Prevention of Glucocorticoid‐Induced Osteoporosis , 2000, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[21]  C. Cooper,et al.  Use of Oral Corticosteroids and Risk of Fractures , 2000 .

[22]  L Abenhaim,et al.  Use of oral corticosteroids in the United Kingdom. , 2000, QJM : monthly journal of the Association of Physicians.

[23]  J. Stross,et al.  Guidelines Have Their Limits , 1999, Annals of Internal Medicine.

[24]  R. Feezor,et al.  Prevention of corticosteroid-induced osteoporosis: results of a patient survey. , 1999, Arthritis and rheumatism.

[25]  M. Mayo-Smith,et al.  Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. , 1999, JAMA.

[26]  M. Hochberg,et al.  Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .

[27]  M. Pringle,et al.  Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study , 1996, BMJ.

[28]  D. Reid,et al.  Steroid induced osteoporosis: an opportunity for prevention? , 1995, Annals of the rheumatic diseases.

[29]  D. Furst,et al.  Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. , 1994, The American journal of medicine.

[30]  P. V. van Riel,et al.  Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis , 1993, Annals of Internal Medicine.

[31]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[32]  J. Fries,et al.  Predictors of fractures in early rheumatoid arthritis. , 1991, The Journal of rheumatology.

[33]  B. Hillner,et al.  A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. , 2003, The Journal of rheumatology.

[34]  M. Hochberg,et al.  Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis , 2001 .

[35]  D. Hosmer,et al.  A review of goodness of fit statistics for use in the development of logistic regression models. , 1982, American journal of epidemiology.